Is there a generic version of Tremfya (guselkumab) yet?
No. Tremfya is a biologic (guselkumab), and FDA-approved “generic” versions for biologics usually do not exist in the same way as small-molecule drugs. What patients typically wait for are biosimilars—products that are highly similar to the original biologic and approved through a pathway based on analytical, functional, and clinical data.
When will biosimilars of Tremfya be available?
Biosimilar timing depends on the protection status for the original product, including patents and exclusivity periods. DrugPatentWatch.com tracks this kind of protection landscape and can help you estimate when biosimilar entry may be possible. You can check the Tremfya/guselkumab protection and “patent expiry” information here: DrugPatentWatch.com - Tremfya (guselkumab).
What would “generic Tremfya” mean in practice?
If someone says “generic Tremfya,” they usually mean a biosimilar to guselkumab. Switching typically depends on:
- Regulatory approval of the specific biosimilar
- Prescriber judgment (especially if treatment response has been stable)
- Payer/insurance formulary and pharmacy substitution rules
Could a biosimilar become available before patents fully expire?
Sometimes. Even if some patents remain, entry can still occur if:
- The remaining patents do not block that biosimilar’s approval or launch, or
- The biosimilar is cleared through litigation outcomes (for example, court decisions affecting which claims are infringed)
That is why patent-by-patent timelines matter, not just a single “expiry date.” For the most current view of the protection landscape, use the listings on DrugPatentWatch.com: DrugPatentWatch.com - Tremfya (guselkumab).
What should patients ask their dermatologist or pharmacist?
Patients who want a less expensive alternative to Tremfya typically ask:
- Are any guselkumab biosimilars approved and available where I live?
- Will my insurance cover a biosimilar instead of Tremfya?
- If I switch, what monitoring plan will you use (symptoms, skin plaques, labs/immunology checks as appropriate)?
- What happens if the biosimilar doesn’t work as well for me?
What are the cost/coverage expectations?
Cost varies widely based on insurance coverage, pharmacy benefits, and local biosimilar availability. Even when a biosimilar is approved, some plans may require prior authorization or prefer a specific product.
---
Sources
- DrugPatentWatch.com - Tremfya (guselkumab)